All Stanford University & Hospital ID holders are now welcome to visit Lane Library! Learn More
Today's Hours: 10:00am - 6:00pm
Filters applied
Did You Mean?
  • Book
    Michael R. Migden, Leon Chen, Sirunya Silapunt, editors.
    Intro -- Preface -- Contents -- Contributors -- Editor Biographies -- Chapter 1: Epidemiology and Risk Factors of Basal Cell Carcinoma -- Epidemiology -- Introduction -- Geography -- Demographics -- Location and Histologic Subtype -- Morbidity and Mortality -- Economic Burden -- Prevention -- Risk Factors -- Introduction -- UV Radiation -- Photosensitizing Medications -- Ionizing Radiation -- Chemical Exposures -- Immunosuppression -- Genes -- Conclusion -- References -- Chapter 2: Pathophysiology of Basal Cell Carcinoma and Its Associated Genetic Syndromes -- Introduction Basal Cell Nevus Syndrome (BCNS) -- Bazex-Dupre-Christol Syndrome -- Rombo Syndrome -- Additional Genetic Syndromes with Increased Risk of Basal Cell Carcinoma -- References -- Chapter 3: Histopathology of Basal Cell Carcinoma and Its Variants -- Introduction -- Common Histologic Features -- Histologic Variants -- Nodular Basal Cell Carcinoma -- Superficial Basal Cell Carcinoma -- Infundibulocystic/Hamartomatous Basal Cell Carcinoma -- Fibroepithelioma of Pinkus -- Infiltrative Basal Cell Carcinoma -- Morpheaform Basal Cell Carcinoma -- Micronodular Basal Cell Carcinoma Clear Cell Basal Cell Carcinoma -- Adenoid Basal Cell Carcinoma -- Pleomorphic Basal Cell Carcinoma -- Keratotic Basal Cell Carcinoma -- Basal Cell Carcinoma with Matrical Differentiation -- Basal Cell Carcinoma with Ductal Differentiation -- Metaplastic Basal Cell Carcinoma -- High-Risk Features -- References -- Chapter 4: Topical Therapy for the Treatment of Basal Cell Carcinoma -- Introduction -- Background -- Mechanism of Action -- Imiquimod -- 5-Fluorouracil -- Ingenol Mebutate -- Efficacy -- Imiquimod -- 5-Fluorouracil -- Ingenol Mebutate -- Safety -- Imiquimod -- 5-Fluorouracil Ingenol Mebutate -- Comparative Studies -- Imiquimod -- Comparison of Different Treatment Regimens of Imiquimod to Vehicle Cream -- Comparison of Imiquimod to Other Treatment Modalities -- 5-Fluorouracil -- Ingenol Mebutate -- Emerging Topical Treatments and Combination Therapies -- Combination Therapies -- Imiquimod Plus CT -- Imiquimod Plus PDT -- Imiquimod Plus Curettage -- Imiquimod Plus MMS -- 5-FU Combination Therapy -- Discussion and Conclusions -- References -- Chapter 5: Local Immunotherapy for Basal Cell Carcinoma with Interferon -- Introduction -- Background Role of the Immune System -- Treatment with Immunostimulatory Agents (ISRX) -- Efficacy -- Low Recurrence Rate -- Normal Skin Markings -- Cosmesis -- Preservation of Function -- No Wound -- All Other Therapeutic Options Remain Open -- Disadvantages of ISRX -- Mechanism of Action of ISRX -- Patient/Tumor Selection -- Interferon Injections -- Preparation of IFN for Injection -- Injection Technique -- Dosage of IFN -- Combination of IFN with IMIQ -- Side Effects -- Recommended Follow-Up for BCC Treated with ISRX -- Conclusion -- References
    Digital Access  Springer 2020